3 Key Takeaways
Plain English Summary- 01Core Finding
A legacy of early medications withdrawn over safety concerns, together with poor efficacy (real-world effectiveness in the trial), and widespread lack of recognition of obesity as a chronic disease contributed to persistent underuse of obesity pharmacotherapy.
- 02Study Evidence
Tested in a expert consensus / perspective at the guideline and clinical review stage.
- 03Practical Meaning
Expert perspective or consensus guidance synthesizing existing studies rather than reporting new randomized trial data.
What This Means for You
Reflecting this paradigm shift, WHO issued global guidelines and included GLP-1 receptor agonists in the Essential Medicines List, albeit for a narrowly defined population. We take a critical historical perspective, charting the highs and lows of obesity medication development and examining the scientific, regulatory, and societal factors that have slowed or impeded the translation of pharmacological advances into safe, effective, and widely accepted treatments for obesity.
The Discovery
Obesity is a chronic, progressive disease associated with disability, increased morbidity, and reduced life expectancy. Global prevalence has risen sharply in recent decades, yet obesity and its treatment-particularly pharmacotherapy -have been highly stigmatised. A legacy of early medications withdrawn over safety concerns, together with poor efficacy (real-world effectiveness in the trial), and widespread lack of recognition of obesity as a chronic disease contributed to persistent underuse of obesity pharmacotherapy. This underuse changed in the 2020s with GLP-1 receptor agonists and, later, multiagonist therapies, with their substantially greater efficacy, safety, and disease-modifying benefits compared with older agents.
How It Works, Simply
This endocrinology research focuses on GLP-1 hormone pathway · Receptor targeting. Researchers evaluated it using an expert consensus / Perspective at the guideline and clinical review stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
A legacy of early medications withdrawn over safety concerns, together with poor efficacy, and widespread lack of recognition of obesity as a chronic disease contributed to persistent underuse of obesity pharmacotherapy.
- 02Study Evidence
Tested in a expert consensus / perspective at the guideline and clinical review stage.
- 03Practical Meaning
Expert perspective or consensus guidance synthesizing existing studies rather than reporting new randomized trial data.
Biological Mechanism & Study Design
Study Design & Cohort
Expert consensus / Perspective
Expert consensus / Perspective · Guideline / Opinion
Biological Pathway & Modality
GLP-1 hormone pathway · Receptor targeting
Intervention: The development of obesity pharmacotherapy: from early challenges and setbacks to
Experimental Findings & Endpoints
Obesity is a chronic, progressive disease associated with disability, increased morbidity, and reduced life expectancy.
Global prevalence has risen sharply in recent decades, yet obesity and its treatment-particularly pharmacotherapy -have been highly stigmatised. A legacy of early medications withdrawn over safety concerns, together with poor efficacy, and widespread lack of recognition of obesity as a chronic disease contributed to persistent underuse of obesity pharmacotherapy.
This underuse changed in the 2020s with GLP-1 receptor agonists and, later, multiagonist therapies, with their substantially greater efficacy, safety, and disease-modifying benefits compared with older agents.
Clinical Translation & Practice Context
Reflecting this paradigm shift, WHO issued global guidelines and included GLP-1 receptor agonists in the Essential Medicines List, albeit for a narrowly defined population.
We take a critical historical perspective, charting the highs and lows of obesity medication development and examining the scientific, regulatory, and societal factors that have slowed or impeded the translation of pharmacological advances into safe, effective, and widely accepted treatments for obesity.
The Bottom Line · Clinical Pearl
“We take a critical historical perspective, charting the highs and lows of obesity medication development and examining the scientific, regulatory, and societal factors that have slowed or impeded the translation of pharmacological advances into safe, effective, and widely accepted treatments for obesity.”
Published in The Lancet Diabetes & Endocrinology · Current Stage: Guideline / Opinion